Intermediate Dose of Intravenous Melphalan in Advanced Multiple Myeloma
作者:
S. Tsakanikas,
K. Papanastasiou,
M. Stamatelou,
A. Maniatis,
期刊:
Oncology
(Karger Available online 1991)
卷期:
Volume 48,
issue 5
页码: 369-371
ISSN:0030-2414
年代: 1991
DOI:10.1159/000226961
出版商: S. Karger AG
关键词: Intravenous melphalan;Myeloma
数据来源: Karger
摘要:
Eighteen patients with advanced multiple myeloma resistant to VAD chemotherapy (vincristine, Adriamycin, dexamethasone) were treated with intravenous melphalan in a single-pulse dose of 50–70 mg/m2. Objective response (≥50% reduction of the monoclonal protein) was observed in 9 patients. The median duration of remission in the responding patients was 6 months and the median survival 11.5 months. The main toxicity noted was bone marrow suppression. We conclude that intermediate doses of intravenous melphalan are a useful therapeutic modality in refractory or relapsing myeloma patie
点击下载:
PDF
(1111KB)
返 回